357 related articles for article (PubMed ID: 14622169)
21. Regional dopamine transporter gene expression in the substantia nigra from control and Parkinson's disease brains.
Counihan TJ; Penney JB
J Neurol Neurosurg Psychiatry; 1998 Aug; 65(2):164-9. PubMed ID: 9703165
[TBL] [Abstract][Full Text] [Related]
22. Levodopa and the progression of Parkinson's disease.
Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
[TBL] [Abstract][Full Text] [Related]
23. Preferential alterations in the mesolimbic dopamine pathway of heterozygous reeler mice: an emerging animal-based model of schizophrenia.
Ballmaier M; Zoli M; Leo G; Agnati LF; Spano P
Eur J Neurosci; 2002 Apr; 15(7):1197-205. PubMed ID: 11982630
[TBL] [Abstract][Full Text] [Related]
24. Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain.
Madras BK; Gracz LM; Fahey MA; Elmaleh D; Meltzer PC; Liang AY; Stopa EG; Babich J; Fischman AJ
Synapse; 1998 Jun; 29(2):116-27. PubMed ID: 9593102
[TBL] [Abstract][Full Text] [Related]
25. L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism.
Kaiser R; Hofer A; Grapengiesser A; Gasser T; Kupsch A; Roots I; Brockmöller J
Neurology; 2003 Jun; 60(11):1750-5. PubMed ID: 12796525
[TBL] [Abstract][Full Text] [Related]
26. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
[TBL] [Abstract][Full Text] [Related]
27. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.
Guigoni C; Aubert I; Li Q; Gurevich VV; Benovic JL; Ferry S; Mach U; Stark H; Leriche L; Håkansson K; Bioulac BH; Gross CE; Sokoloff P; Fisone G; Gurevich EV; Bloch B; Bezard E
Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S25-9. PubMed ID: 15885624
[TBL] [Abstract][Full Text] [Related]
28. [Effect of electroacupuncture scalp point-through-point therapy on the expression of tyrosine hydroxylase and dopamine transporter mRNAs in substantia nigra of Parkinson's disease model rats].
Wang S; Qi XJ; Han D
Zhongguo Zhen Jiu; 2009 May; 29(5):391-4. PubMed ID: 19489498
[TBL] [Abstract][Full Text] [Related]
29. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1.
Goldberg MS; Pisani A; Haburcak M; Vortherms TA; Kitada T; Costa C; Tong Y; Martella G; Tscherter A; Martins A; Bernardi G; Roth BL; Pothos EN; Calabresi P; Shen J
Neuron; 2005 Feb; 45(4):489-96. PubMed ID: 15721235
[TBL] [Abstract][Full Text] [Related]
30. Lower nucleus accumbens α-synuclein load and D3 receptor levels in Parkinson's disease with impulsive compulsive behaviours.
Barbosa P; Hapuarachchi B; Djamshidian A; Strand K; Lees AJ; de Silva R; Holton JL; Warner TT
Brain; 2019 Nov; 142(11):3580-3591. PubMed ID: 31603207
[TBL] [Abstract][Full Text] [Related]
31. Expression of dopamine receptors and transporter in neuroendocrine gastrointestinal tumor cells.
Lemmer K; Ahnert-Hilger G; Höpfner M; Hoegerle S; Faiss S; Grabowski P; Jockers-Scherübl M; Riecken EO; Zeitz M; Scherübl H
Life Sci; 2002 Jun; 71(6):667-78. PubMed ID: 12072155
[TBL] [Abstract][Full Text] [Related]
32. Selective alterations of gene expression in mice induced by MPTP.
Xu Z; Cawthon D; McCastlain KA; Slikker W; Ali SF
Synapse; 2005 Jan; 55(1):45-51. PubMed ID: 15499605
[TBL] [Abstract][Full Text] [Related]
33. [Role and regulation of dopamine D1 receptors in the striatum: implications for the genesis of dyskinesia in Parkinson's disease].
Corvol JC; Girault JA; Hervé D
Rev Neurol (Paris); 2006 Jun; 162(6-7):691-702. PubMed ID: 16840977
[TBL] [Abstract][Full Text] [Related]
34. Altered Expression of D1 and D2 Dopamine Receptors in Vagal Neurons Innervating the Gastric Muscularis Externa in a Parkinson's Disease Rat Model.
Wang ZY; Lian H; Zhou L; Zhang YM; Cai QQ; Zheng LF; Zhu JX
J Parkinsons Dis; 2016 May; 6(2):317-23. PubMed ID: 27164043
[TBL] [Abstract][Full Text] [Related]
35. Dopamine D-1 receptor and cyclic AMP-dependent phosphorylation in Parkinson's disease.
Cash R; Raisman R; Ploska A; Agid Y
J Neurochem; 1987 Oct; 49(4):1075-83. PubMed ID: 2887632
[TBL] [Abstract][Full Text] [Related]
36. L-Dopa-responsive Parkinson's syndrome in association with phenylketonuria: In vivo dopamine transporter and D2 receptor findings.
Evans AH; Costa DC; Gacinovic S; Katzenschlager R; O'sullivan JD; Heales S; Lee P; Lees AJ
Mov Disord; 2004 Oct; 19(10):1232-6. PubMed ID: 15390012
[TBL] [Abstract][Full Text] [Related]
37. Adaptive gene expression changes on the healthy side of parkinsonian rats.
Capper-Loup C; Frey CM; Rebell D; Kaelin-Lang A
Neuroscience; 2013 Mar; 233():157-65. PubMed ID: 23270858
[TBL] [Abstract][Full Text] [Related]
38. Dopamine D(1) receptor expression in human basal ganglia and changes in Parkinson's disease.
Hurley MJ; Mash DC; Jenner P
Brain Res Mol Brain Res; 2001 Mar; 87(2):271-9. PubMed ID: 11245931
[TBL] [Abstract][Full Text] [Related]
39. Rationale for dopamine agonist use as monotherapy in Parkinson's disease.
Schwarz J
Curr Opin Neurol; 2003 Dec; 16 Suppl 1():S27-33. PubMed ID: 15180135
[TBL] [Abstract][Full Text] [Related]
40. Localization of dopaminergic markers in the human subthalamic nucleus.
Augood SJ; Hollingsworth ZR; Standaert DG; Emson PC; Penney JB
J Comp Neurol; 2000 May; 421(2):247-55. PubMed ID: 10813785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
